ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals

Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 5)

Abstract

Since its publication in 1997, the ICH guideline on the Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (“ICH S6”) has fostered consistency while maintaining the necessary flexibility for testing within and across a variety of product classes. Successful implementation of a product-specific science-based “case-by-case” approach however has required individuals with a broad knowledge of toxicological processes and the ability to integrate data from molecular biology, pharmacology, physiology, pharmacokinetics, and pathology. Importantly, the “case-by-case” approach only works if there is an understanding of the science and an acceptance by both regulators and industry that the interpretation of the data has to reflect best scientific practice and that no study in experimental animals can predict with certainty the outcome in humans. As such, a greater dialogue between industry and regulatory authorities has been needed early and in some cases throughout development to ensure that the decision on how a product should be tested not only meets the stringencies of the regulatory authorities but is also designed to improve the predictive value for extrapolating to humans. This dialogue between industry and regulatory authorities continued to the ICH Expert Working Group charged with formulating the addendum to ICH S6(ICH S6R(1) finalized at step 4 in June 2011), guidance based on the accumulated and collective experience of the safety assessment of biotechnology-derived pharmaceuticals in the 14 years since the finalization of ICH S6.

Keywords

Toxicity Fermentation Europe Lymphoma Cage 

References

  1. Bass R, Kleeburg U, Schroder H et al (1992) Current guidelines for the preclinical safety assessment of therapeutic proteins. Toxicol Lett 64/65:339–347CrossRefGoogle Scholar
  2. Bornstein GG, Klakamp SL, Andrews L, Boyle WJ, Tabrizi M (2009) Surrogate approaches in development of monoclonal antibodies. Drug Discov Today 14(23/24):1159–1165PubMedCrossRefGoogle Scholar
  3. Bowman CJ, Chmielewski G, Oneda S, Finco D, Boucher MA, Todd M (2010) Embryo-fetal development toxicity of figitumumab, an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in cynomolgus monkeys. Birth Defects Res B Dev Reprod Toxicol 89(4):326–338PubMedCrossRefGoogle Scholar
  4. Brennan FR, Shaw L, Wing MG, Robinson C (2004) Preclinical safety testing of biopharmaceuticals. Mol Biotechnol 27:59–74PubMedCrossRefGoogle Scholar
  5. Buckley LA, Benson K, Davis-Bruno K, Dempster M, Finch GL, Harlow P, Haggerty HG, Hart T, Kinter L, Leighton JK, McNulty J, Roskos L, Saber H, Stauber A, Tabrizi M (2008) Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop. Int J Toxicol 27(4):303–312PubMedCrossRefGoogle Scholar
  6. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E (2009) Monoclonal antibody-induced cytokine release syndrome. Expert Rev Clin Immunol 5(5):499–521PubMedCrossRefGoogle Scholar
  7. Bugelski P, Volk A, Walker MR, Krayer JH, Martin P, Descotes J (2010) Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol 29(5):435–466PubMedCrossRefGoogle Scholar
  8. Bussiere J (2008) Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opin Drug Metab Toxicol 4(7):871–877PubMedCrossRefGoogle Scholar
  9. Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, Beyer J, Horvath C (2009) Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 28:230–253PubMedCrossRefGoogle Scholar
  10. Bussiere JL, Leach MW, Price KD, Mounho BJ, Lighfoot-Dunn R (2011) Survey results on the use of the tissue cross-reactivity immunohistochemistry assay. Regul Toxicol Pharmacol 59:493–502PubMedCrossRefGoogle Scholar
  11. Buttel IC, Chamberlain P, Chowers Y et al (2011) Taking Immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39:100–109PubMedCrossRefGoogle Scholar
  12. Cavagnaro JA (1992a) Misconceptions within biotechnology. In: D’Arcy PF, Harmon DWG (eds) Proceedings of the first conference on harmonisation, Brussels, 1991. The Queen’s University of Belfast, Belfast, pp 301–307Google Scholar
  13. Cavagnaro JA (1992b) Science-based approach to preclinical safety evaluation of biotechnology products. Pharmaceut Eng 12:32–33Google Scholar
  14. Cavagnaro JA (2002) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 1:469–475PubMedCrossRefGoogle Scholar
  15. Cavagnaro JA (ed) (2008a) Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. Wiley, New YorkGoogle Scholar
  16. Cavagnaro JA (2008b) Assessment of carcinogenic risk of biopharmaceuticals. In: Cavagnaro JA (ed) Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials. Wiley, New York, pp 399–477CrossRefGoogle Scholar
  17. Cavagnaro J (2010) Considerations for the preclinical safety evaluation of biopharmaceuticals. In: Charlene A (ed) McQueen, comprehensive toxicology, vol 3. Academic, Oxford, pp 29–51CrossRefGoogle Scholar
  18. Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V (2009) Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. mAbs 1(5):505–516PubMedCrossRefGoogle Scholar
  19. Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Dempster AM, De Haan L, Jones K, Pullen N, de Boer AS, Sims J and Ragan CI (2012) The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in the use of non-human primates. Regul Toxicol Pharmacol 62(2):347–354Google Scholar
  20. Chellman GJ, Bussiere JL, Makori N, Martin PL, Ooshima Y, Weinbauer GF (2009) Developmental and reproductive toxicology studies in nonhuman primates. Birth Defects Res B 86:446–462CrossRefGoogle Scholar
  21. Clarke J, Hurst C, Martin P, Vahle J, Ponce R, Mounho B, Heidel S, Andrews L, Reynolds T, Cavagnaro J (2008) Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate? Regul Toxicol Pharmacol 50:2–22PubMedCrossRefGoogle Scholar
  22. Claude JR (1992) Difficulties in conceiving and applying guidelines for the safety evaluation of biotechnologically-produced drugs: some examples. Toxicol Lett 64(65):349–355PubMedCrossRefGoogle Scholar
  23. Dayan AD (1987) Rationality and regulatory requirements- a view from Britain. In: Grahm CE (ed) Preclinical safety of biotechnology products intended for human use: clinical and biological research, vol 235. Alan R. Liss, New York, pp 89–106Google Scholar
  24. Dayan AD (1995) Safety evaluation of biological and biotechnology-derived medicines. Toxicology 105:59–68PubMedCrossRefGoogle Scholar
  25. Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R (2010) Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161:512–526PubMedCrossRefGoogle Scholar
  26. EMEA/CHMP/SWP/28367/07Google Scholar
  27. FDA (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use, 1997. http://www.fda.gov
  28. Findlay L, Eastwood D, Ball C, Robinson CJ, Bird C, Wadhwa M, Thorpe R, Stebbings R, Poole S (2011) Comparison of novel methods for predicting the risks of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Methods 371(1–2):131–142Google Scholar
  29. Finkle BS (1987) Genetically engineered drugs: toxicology with a difference. In: Grahm CE (ed) Preclinical safety of biotechnology products intended for human use: clinical and biological research, vol 235. Alan R. Liss, New York, pp 161–167Google Scholar
  30. Friedrich A, Olejniczak K (2010) Evaluation of carcinogenicity studies for medicinal products for human use authorized via the European centralized procedure (1995–2009). Regul Toxicol Pharmacol 60(2):225–248CrossRefGoogle Scholar
  31. Galbraith WM (1987) Symposium discussion. In: CE Grahm (ed) Preclinical safety of biotechnology products intended for human use: clinical and biological research, vol 235. Alan R. Liss, New York, pp 189–206Google Scholar
  32. Giss HE (1987) Foreword. In: Grahm CE (ed) Preclinical safety of biotechnology products intended for human use: clinical and biological research, vol 235. Alan R. Liss, New York, pp xiii–xvGoogle Scholar
  33. Gocke E, Albertini S, Brendel-Schwaab S, Muller L, Suter W et al (1999) Genotoxicity testing of biotechnology-derived products. Report of GUM task force. Mutant Res 436:137–156CrossRefGoogle Scholar
  34. Griffith SA, Lumley CE (1998) Non-clinical safety studies for biotechnologically-derived pharmaceuticals: conclusions form an international workshop. Hum Exp Toxicol 17:63083Google Scholar
  35. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325–338PubMedCrossRefGoogle Scholar
  36. Hayakawa T (1992) Current regulatory situation in Japan with respect to the preclinical safety testing for biotechnology products intended for human use. In: D’Arcy PF, Harmon DWG (eds) Proceedings of the first conference on harmonisation, Brussels 1991. The Queen’s University of Belfast, Belfast, pp 296–301Google Scholar
  37. Hayes TJ, Cavagnaro JA (1992) Progress and challenges in the preclinical assessment of cytokines. Toxicol Lett 64(65):291–297PubMedCrossRefGoogle Scholar
  38. Henck JW, Hilbish KG, Serabian MA, Cavagnaro JA, Hendrickx AG, Agnish ND, Kung ADH, Mordenti J (1996) Reproductive toxicity testing of therapeutic biotechnology agents. Teratology 53:185–195PubMedCrossRefGoogle Scholar
  39. Hohbach C (1992) Safety in biotechnology progress and problems, industrial point of view. In: D’Arcy PF, Harmon DWG (eds) Proceedings of the first conference on harmonisation, Brussels 1991. The Queen’s University of Belfast, Belfast, pp 307–316Google Scholar
  40. Horvath CJ, Milton MN (2009) The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event? Toxicol Pathol 37:372–383PubMedCrossRefGoogle Scholar
  41. ICH M3(R2) (2010): Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.ich.org
  42. ICH S6 Preclinical safety evaluation of biotechnology-derived pharmaceuticals (1997) http://www.ich.org
  43. ICH S6R(1): Preclinical safety evaluation of biotechnology-derived pharmaceuticals. http://www.ich.org
  44. ICHS5A Detection of toxicity to reproduction for medicinal productsGoogle Scholar
  45. Jarvis P, Srivastav S, Vogelwedde E, Stewart J, Mitchard T, Weinbauer GF (2010) The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations. Birth Defects Res B 89:175–187Google Scholar
  46. Kikuchi Y (1992) Panel presentation safety: biotechnology. In: D’Arcy PF, Harmon DWG (eds) Proceedings of the first conference on harmonisation, Brussels 1991. The Queen’s University of Belfast, Belfast, pp 316–319Google Scholar
  47. Leach MW, Halpern WG, Johnson CW, Rojko JL, MacLachlan TK, Chan CM, Galbreath EJ, Ndifor AM, Blanset DL, Polack E, Cavagnaro JA (2010) Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals; history, experience, methodology, and future directions. Toxicol Pathol 38:1138–1166PubMedCrossRefGoogle Scholar
  48. Liedert B, Bassus S, Schneider CK, Kalinke U, Lower J (2007) Safety of Phase I clinical trials with monoclonal antibodies in Germany – the regulatory requirements viewed in the aftermath of the TGN1412 disaster. Int J Clin Pharmacol Ther 45(1):1–9PubMedGoogle Scholar
  49. Lowe P, Tannenbaum S, Wu K, Lloyd P, Sims J (2009) On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamics ­models. Basic Clin Pharmacol Toxicol 106:195–209PubMedCrossRefGoogle Scholar
  50. Martin PL, Breslin W, Rocca M, Wright D, Cavagnaro J (2009) Consideration in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Defects Res B 86:176–203CrossRefGoogle Scholar
  51. Martin PL, Weinbauer GF (2010) Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int J Toxicol 29:552–568PubMedCrossRefGoogle Scholar
  52. Milton MN, Horvath CJ (2009) The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development. Toxicol Pathol 37:363–371PubMedCrossRefGoogle Scholar
  53. Nakazawa T, Kai S, Kawai M, Maki E, Sagami F, Onodera H, Kitajima S, Inoue T (2004) “Points to Consider” regarding safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies (English Translation). J Toxicol Sci 29:497–504PubMedCrossRefGoogle Scholar
  54. Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B 86:328–344CrossRefGoogle Scholar
  55. Ponce R, Abad L, Amaravadi L, Gelzieichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens I, Kawabata T, Mauer C, Mounho B, Rup B, Shankdar G, Smith H, Thomas P, Wierda D (2009) Immunogenicity of biotechnology-derived therapeutics: assessment and interpretation of nonclinical studies. Regul Toxicol Pharmacol 54:164–182PubMedCrossRefGoogle Scholar
  56. Roskos L, Schneider A, Vainshtein I, Schwickart M, Lee R, Lu H, Faggioni R, Liang M (2011) PK-PD modeling of protein drugs: implications in assay development. Bioanalysis 3(6):659–675PubMedCrossRefGoogle Scholar
  57. Ryan AM, Terrell TG (2002) Biotechnology and its products. In: Handbook of toxicologic pathology, 2nd edn. Academic, New York, pp 479–500Google Scholar
  58. Schneider CK, Kalinke I, Lower J (2006) TGN1412 – a regulator’s perspective. Nat Biotechnol 24(4):368Google Scholar
  59. Serabian MA, Pilaro AM (1999) Safety assessment of biopharmaceuticals: ICH and beyond. Toxicol Pathol 27:27–31PubMedCrossRefGoogle Scholar
  60. Simister N (2003) Placental transport of immunoglobulin G. Vaccine 21:3365–3369PubMedCrossRefGoogle Scholar
  61. Sims J (2001) Assessment of biotechnology products for therapeutic use. Toxicol Lett 120:59–66PubMedCrossRefGoogle Scholar
  62. Sistare FD, Morton D, Alden C, Christensen J, Keller D et al (2010) An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol Pathol 39(716–744):2011Google Scholar
  63. Stebbings R, Findly L, Edwards C, Eastwood D, Bird C, North D, Mistry Y, Dilger P, Liefooghe E, Cludts I, Fox B, Tarrant G, Robinson J, Meager T, Dolman C, Thorpe SJ, Bristow A, Wadhwa M, Thorpe R, Poole S (2007) “Cytokine storm” in a Phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve the preclinical testing of immunotherapeutics. J Immunol 179:3325–3331PubMedGoogle Scholar
  64. Stebbings R, Pool S, Thorpe R (2009) Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 20(6):673–677PubMedCrossRefGoogle Scholar
  65. Stewart J (2009) Developmental toxicity testing of monoclonal antibodies: an enhanced pre-and postnatal study design option. Reprod Toxicity 28:220–225CrossRefGoogle Scholar
  66. Suntharalingham G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028CrossRefGoogle Scholar
  67. Tabrizi MA, Roskos LK (2007) Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 12(13/14):540–547PubMedCrossRefGoogle Scholar
  68. Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L (2009) Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 14(5–6):298–305PubMedCrossRefGoogle Scholar
  69. Terrell TG, Green JD (1994) Issues with biotechnology products in toxicologic pathology. Toxicol Pathol 22:187–193PubMedCrossRefGoogle Scholar
  70. Thomas JA (1995) Recent developments and perspectives of biotechnology-derived products. Toxicology 105:7–22PubMedCrossRefGoogle Scholar
  71. Tibbitts J, Cavagnaro JA, Haller CA, Marafino B, Andrews PA, Sullivan JT (2010) Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regul Toxicol Pharmacol 58:243–251PubMedCrossRefGoogle Scholar
  72. Vahle JL, Finch GL, Heidel SM, Hovland DN, Ivens I, Parker S, Ponce RA, Sachs C, Steigerwalt R, Short B, Todd MD (2010) Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations. Toxicol Pathol 38:522–553PubMedCrossRefGoogle Scholar
  73. Vargas HM, Bass AS, Breidenbach A, Feldman HS, Gintant GA, Harmer AR, Heath B, Hoffman P, Lagrutta A, Leishman D, McMahon N, Mittelstadt S, Polonchuk L, Pugsley MK, Satata JJ, Valentin J-P (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58:72–76PubMedCrossRefGoogle Scholar
  74. Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, Mueller-Berghaus J, Pallardy M, Van der Laan JW (2010) In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine 51(2):213–215PubMedCrossRefGoogle Scholar
  75. Weinbauer GF, Niehoff M, Niehaus M, Srivastav S, Fuchs A, Van Esch E, Cline JM (2008) Physiology and endocrinology of the ovarian cycle in macaques. Toxicol Pathol 36(7S):7S–23SPubMedCrossRefGoogle Scholar
  76. Zbinden G (1987) Biotechnology products intended for human use, toxicological targets and research strategies. In: Grahm CE (ed) Preclinical safety of biotechnology products intended for human use: clinical and biological research, vol 235. Alan R. Liss, New York, pp 143–159Google Scholar
  77. Zbinden G (1990) Safety evaluation of biotechnology products. Drug Saf 5(suppl 1):58–64PubMedCrossRefGoogle Scholar
  78. Zbinden G (1991) Predictive value of animal studies in toxicology. Regul Toxicol Pharmacol 14:167–177PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2013

Authors and Affiliations

  1. 1.Access BIOBoyceUSA
  2. 2.Integrated Biologix GmbHBaselSwitzerland

Personalised recommendations